成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Journal of Drug Delivery Science and Technology >>article
Journal of Drug Delivery Science and Technology

Journal of Drug Delivery Science and Technology

IF: 4.5
Download PDF

Topical delivery of tofacitinib citrate loaded novel nanoemulgel for the management of 2,4-Dichlorodinitrobenzene induced atopic dermatitis in mice model

Published:1 February 2023 DOI: 10.1016/j.jddst.2022.104145
Srividya Atmakuri , Shweta Nene , Harsha Jain , Ramesh Joga , Geetanjali Devabattula , Chandraiah Godugu , Saurabh Srivastava

Abstract

Tofacitinib is an inhibitor of Janus kinases (JAK), which is approved to manage moderate to severe conditions of rheumatoid arthritis, showing inadequate response or intolerance to methotrexate. Currently, several clinical trials are in progress, emphasizing the potential study of tofacitinib in managing inflammatory skin disorders like atopic dermatitis and psoriasis. The present research study includes the formulation and characterization of tofacitinib citrate-loaded nanoemulgel for the topical treatment of atopic dermatitis. Tofacitinib exhibited enhanced solubility in the combination of eugenol (oil) and dimethyl sulfoxide (co-solvent), tween-20 (surfactant), along with Transcutol-P (co-surfactant). The study concentration selected for the present work is 0.5% (w/w) of tofacitinib citrate loaded into nanoemulgel. The tofacitinib citrate-loaded nanoemulsion was prepared by the spontaneous nanoemulsion method and characterized by particle size, PDI, transmittance and visual appearance.

Further, a novel nanoemulgel was prepared using SEPINEO? P 600 gel base and evaluated for its pH, viscosity, spreadability, release behavior and drug content for two months. The present work also evaluated the efficacy of optimized tofacitinib citrate-loaded nanoemulgel in the 2,4-Dinitrochlorobenzene induced atopic dermatitis-like symptoms in the BALB/c mice model. In vivo efficacy study demonstrated a significant reduction in dermatitis score and pro-inflammatory cytokine levels in skin homogenates of tofacitinib citrate nanoemulgel treated mice group. Results from animal studies depicted an enhanced activity of tofacitinib citrate nanoemulgel compared to free drug. The tofacitinib citrate nanoemulgel could be a clinically translatable, safer topical formulation for managing atopic dermatitis.

Substances (7)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Dimethyl sulfoxide 67-68-5 C2H6OS 1344 suppliers $15.00-$120900.00
Eugenol 97-53-0 C10H12O2 802 suppliers $5.00-$2271.36
Methotrexate 59-05-2 C20H22N8O5 737 suppliers $8.00-$11728.00
Polysorbate 20 9005-64-5 C26H50O10 656 suppliers $12.00-$6080.49
Tofacitinib citrate 540737-29-9 C16H20N6O.C6H8O7 636 suppliers $8.00-$2340.00
2,4-Dinitrochlorobenzene 97-00-7 C6H3ClN2O4 11 suppliers $17.67-$590.00
600#P 1 suppliers Inquiry

Similar articles

IF:2.9

Baricitinib for the treatment of atopic dermatitis.

Journal of Dermatological Treatment Amelia Melo, Jose Manuel Carrascosa,etc Published: 1 August 2022
IF:4.7

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

Drug Design, Development and Therapy V. Di Lernia,?F. Bardazzi,etc Published: 29 January 2016
IF:5.3

Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy.

ACS Applied Nano Materials Ruma Maji, Niladri Shekhar Dey,etc Published: 25 June 2014